Your browser doesn't support javascript.
loading
Unlocking the puzzle: non-defining mutations in SARS-CoV-2 proteome may affect vaccine effectiveness.
Ulzurrun, Eugenia; Grande-Pérez, Ana; Del Hoyo, Daniel; Guevara, Cesar; Gil, Carmen; Sorzano, Carlos Oscar; Campillo, Nuria E.
Affiliation
  • Ulzurrun E; Center for Biological Research Margarita Salas, Spanish National Research Council (CSIC), Madrid, Spain.
  • Grande-Pérez A; National Center for Biotechnology, Spanish National Research Council (CSIC), Madrid, Spain.
  • Del Hoyo D; Institute of Mathematical Sciences, Spanish National Research Council (CSIC), Madrid, Spain.
  • Guevara C; Department of Cellular Biology, Genetics, and Physiology, University of Malaga, Málaga, Spain.
  • Gil C; National Center for Biotechnology, Spanish National Research Council (CSIC), Madrid, Spain.
  • Sorzano CO; Mechatronics and Interactive Systems - MIST Research Center, Universidad Tecnológica Indoamérica, Quito, Ecuador.
  • Campillo NE; Center for Biological Research Margarita Salas, Spanish National Research Council (CSIC), Madrid, Spain.
Front Public Health ; 12: 1386596, 2024.
Article in En | MEDLINE | ID: mdl-39228849
ABSTRACT

Introduction:

SARS-CoV-2 variants are defined by specific genome-wide mutations compared to the Wuhan genome. However, non-clade-defining mutations may also impact protein structure and function, potentially leading to reduced vaccine effectiveness. Our objective is to identify mutations across the entire viral genome rather than focus on individual mutations that may be associated with vaccine failure and to examine the physicochemical properties of the resulting amino acid changes. Materials and

methods:

Whole-genome consensus sequences of SARS-CoV-2 from COVID-19 patients were retrieved from the GISAID database. Analysis focused on Dataset_1 (7,154 genomes from Italy) and Dataset_2 (8,819 sequences from Spain). Bioinformatic tools identified amino acid changes resulting from codon mutations with frequencies of 10% or higher, and sequences were organized into sets based on identical amino acid combinations.

Results:

Non-defining mutations in SARS-CoV-2 genomes belonging to clades 21 L (Omicron), 22B/22E (Omicron), 22F/23A (Omicron) and 21J (Delta) were associated with vaccine failure. Four sets of sequences from Dataset_1 were significantly linked to low vaccine coverage one from clade 21L with mutations L3201F (ORF1a), A27- (S) and G30- (N); two sets shared by clades 22B and 22E with changes A27- (S), I68- (S), R346T (S) and G30- (N); and one set shared by clades 22F and 23A containing changes A27- (S), F486P (S) and G30- (N). Booster doses showed a slight improvement in protection against Omicron clades. Regarding 21J (Delta) two sets of sequences from Dataset_2 exhibited the combination of non-clade mutations P2046L (ORF1a), P2287S (ORF1a), L829I (ORF1b), T95I (S), Y145H (S), R158- (S) and Q9L (N), that was associated with vaccine failure.

Discussion:

Vaccine coverage associations appear to be influenced by the mutations harbored by marketed vaccines. An analysis of the physicochemical properties of amino acid revealed that primarily hydrophobic and polar amino acid substitutions occurred. Our results suggest that non-defining mutations across the proteome of SARS-CoV-2 variants could affect the extent of protection of the COVID-19 vaccine. In addition, alteration of the physicochemical characteristics of viral amino acids could potentially disrupt protein structure or function or both.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteome / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Mutation Limits: Humans Country/Region as subject: Europa Language: En Journal: Front Public Health Year: 2024 Document type: Article Affiliation country: España Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteome / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Mutation Limits: Humans Country/Region as subject: Europa Language: En Journal: Front Public Health Year: 2024 Document type: Article Affiliation country: España Country of publication: Suiza